Qiaonan Duan
Affiliations: | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Google:
"Qiaonan Duan"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Hodos R, Zhang P, Lee HC, et al. (2018) Cell-specific prediction and application of drug-induced gene expression profiles. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 23: 32-43 |
Niepel M, Hafner M, Duan Q, et al. (2017) Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nature Communications. 8: 1186 |
Sangodkar J, Perl A, Tohme R, et al. (2017) Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation |
Niepel M, Hafner M, Duan Q, et al. (2017) Abstract IA05: New methods and better theory for pre-clinical cancer pharmacogenomics Cancer Research. 77 |
Duan Q, Reid SP, Clark NR, et al. (2016) L1000CDS(2): LINCS L1000 characteristic direction signatures search engine. Npj Systems Biology and Applications. 2 |
Wang Z, Monteiro CD, Jagodnik KM, et al. (2016) Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. Nature Communications. 7: 12846 |
Kuleshov MV, Jones MR, Rouillard AD, et al. (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research |
Dohlman A, Zaman S, Duan Q, et al. (2016) Predicting adverse cardiovascular events for tyrosine kinase inhibitors from molecular features F1000research. 5 |
Hafner M, Niepel M, Duan Q, et al. (2016) Abstract 788: Transcriptional landscape of drug response guides the design of potent and synergistic drug combinations Cancer Research. 76: 788-788 |
Hafner M, Niepel M, Duan Q, et al. (2015) Abstract PR16: Transcriptional landscape of drug response guides the design of specific and potent drug combinations Cancer Research. 75 |